None

Bosutinib/Bosutinib and Osimertinib are two targeted drugs used to treat different types of cancer, but there are significant differences in their mechanisms of action, indications, clinical applications and adverse reactions.

Bosutinib is a tyrosine kinase inhibitor mainly used to treat chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Its main effect is to target the BCR-ABL fusion protein, which is a common cancer-causing protein in chronic myelogenous leukemia. Bosutinib inhibits the activity of this protein to prevent the proliferation and growth of cancer cells, thereby achieving therapeutic effects. The drug has clinically shown efficacy against a variety of resistance mutations, particularly in some patients who have developed resistance to other tyrosine kinase inhibitors (TKIs) such as imatinib.

Osimertinib is a third-generation tyrosine kinase inhibitor mainly used to treat non-small cell lung cancer (NSCLC), especially those with EGFR T790M mutation. EGFR (epidermal growth factor receptor) mutations are common driver mutations in many patients with non-small cell lung cancer, and the T790M mutation often leads to resistance to first- and second-generation EGFR TKIs (such as gefitinib and erlotinib). Osimertinib effectively controls tumor growth by selectively inhibiting the activity of EGFR mutants, while having relatively little impact on normal cells, so its safety is relatively high.

In terms of pharmacokinetics, bosutinib has high oral bioavailability and a moderate half-life in the body, allowing patients to maintain stable drug concentrations when taking it. The pharmacokinetic characteristics of osimertinib make it suitable for long-term treatment, and the expected blood concentration can usually be achieved with one dose, making it easy for patient management.

There are also differences between the two in terms of adverse reactions. Common adverse reactions of bosutinib include diarrhea, abnormal liver function, fatigue, etc. These side effects can in most cases be alleviated through symptomatic treatment. In contrast, the adverse reactions of osimertinib include rash, diarrhea, dry cough, etc., and some patients may develop serious pulmonary complications, such as interstitial lung disease. Therefore, patients need to undergo regular pulmonary assessment while taking osimertinib to ensure that potential serious side effects are detected and managed promptly.

In terms of clinical use, the indications of bosutinib are mainly focused on hematological tumors, while osimertinib is targeted on solid tumors such as lung cancer. For different types of cancer, doctors will choose appropriate drugs for treatment based on the patient's specific condition and genetic test results. In addition, the use of the two also involves different monitoring indicators and evaluation standards. For example, during the treatment of bosutinib, doctors will pay attention to the patient's hematological indicators, while during the treatment of osimertinib, the main focus is on the patient's tumor load changes and imaging evaluation results.

References:https://www.proquest.com/scholarly-journals/alectinib-bosutinib-osimertinib-cardiac/docview/2557554294/se-2